AngioDynamics Company Profile (NASDAQ:ANGO)

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

AngioDynamics, Inc. (NASDAQ:ANGO) released its quarterly earnings results on Thursday, September, 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.16 by $0.04. The company had revenue of $85.40 million for the quarter, compared to analyst estimates of $86.12 million. AngioDynamics had a net margin of 1.64% and a return on equity of 4.83%. AngioDynamics's revenue for the quarter was down 3.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.17 EPS. View AngioDynamics' Earnings History.

AngioDynamics is scheduled to release their next quarterly earnings announcement on Thursday, January, 4th 2018. View Earnings Estimates for AngioDynamics.

AngioDynamics issued an update on its FY18 earnings guidance on Thursday, September, 28th. The company provided EPS guidance of $0.64-0.68 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.67. The company issued revenue guidance of $352-359 million, compared to the consensus revenue estimate of $355.58 million.

5 brokerages have issued 1 year target prices for AngioDynamics' shares. Their forecasts range from $16.00 to $21.00. On average, they expect AngioDynamics' share price to reach $18.50 in the next year. View Analyst Ratings for AngioDynamics.

Here are some recent quotes from research analysts about AngioDynamics stock:

• 1. According to Zacks Investment Research, "AngioDynamics reported a dismal first quarter of fiscal 2018 wherein adjusted earnings and revenues missed the Zacks Consensus Estimate. The company reaffirmed its guidance for fiscal 2018. AngioDynamicis rides on the market’s solid response to Solero, especially within the Microwave Ablation space. Growth in the core Angiographic Catheter business is also likely to fortify the company’s footprint in the global space. On the flipside, AngioDynamics recalled the Acculis Microwave Tissue Ablation System under the Oncology and Surgery segment last quarter. The company also had a high outstanding debt level at the end of the first quarter. Higher debts impose certain operating and financial restrictions which might limit the execution of the company’s core business strategies. AngioDynamics traded below the broader industry in the past year." (10/3/2017)
• 2. Cantor Fitzgerald analysts commented, "F3Q17 Result Summary. F3Q17 total revenues of $85.6M (down 2.0% y/y), was $3.2M below our estimate of $88.8M and $2.7M below FactSet consensus of $88.3M." (3/30/2017)

Some companies that are related to AngioDynamics include Varex Imaging (VREX), Akcea Therapeutics (AKCA), Acorda Therapeutics (ACOR), Repligen Corporation (RGEN), Esperion Therapeutics (ESPR), Dynavax Technologies Corporation (DVAX), LHC Group (LHCG), IRHYTHM TECH (IRTC), Sangamo Therapeutics (SGMO), Lexicon Pharmaceuticals (LXRX), OraSure Technologies (OSUR), Epizyme (EPZM), Dermira (DERM), Genomic Health (GHDX), Glaukos Corporation (GKOS), The Ensign Group (ENSG), Accelerate Diagnostics (AXDX) and Arena Pharmaceuticals (ARNA).

AngioDynamics' management team includes the folowing people:

• Howard W. Donnelly, Independent Chairman of the Board
• James C. Clemmer, President, Chief Executive Officer, Director
• Michael Greiner, Chief Financial Officer, Executive Vice President
• Gary Barrett, Senior Vice President,Quality and Regulatory Affairs
• Ben Davis, Senior Vice President, Business Development
• Barbara Kucharczyk, Senior Vice President-Global Operations
• Stephen A. Trowbridge, Senior Vice President, General Counsel
• Eileen O'Shea Auen, Director
• Jan Stern Reed, Director
• David F. Burgstahler, Independent Director

Shares of AngioDynamics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of AngioDynamics stock can currently be purchased for approximately $17.69.